Gene Therapy for Neurological Disorders and Brain Tumors
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
edited by E. Antonio Chiocca and Xandra O. Breakefield, 458 pp., ill., Totowa, NJ, Humana Press, 1998, $165.00
The methodologies employed in gene therapy are rapidly improving, leading to safer delivery vehicles that are more amenable for application to CNS disorders. Because the field is progressing so quickly, it is instructive to review periodically experimental data relating to gene delivery and to discuss the technological and clinical advances of gene therapeutic strategies, as this allows one to assess and devise new approaches effectively. Gene Therapy for Neurological Disorders and Brain Tumors seeks to accomplish this mission and its editors have assembled contributions from many investigators who work productively in gene therapy.
An overview discusses cell types that comprise the CNS and viral vectors that are currently used, and outlines the issues regarding safety and efficacy of gene therapy (i.e., transgene expression duration, vector-mediated toxicity, and immune response).
The volume has an unbalanced representation of the virus vectors currently used by investigators in the CNS gene delivery field. For example, there is a comprehensive discussion of retroviral vectors including life cycle, vector design, packaging cell lines, and packaging protocols. However, such murine-based vectors are poor choices for postmitotic neurons or quiescent glia. By contrast, adenoviral vectors, which have seen considerable use in the CNS, are covered in a rudimentary fashion that does not provide enough depth on these well-tested vectors. The chapters on HSV vectors are more …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David Beversdorf and Dr. Ryan Townley
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
ARTICLES
Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell lineM.R. Rosenfeld, P. Meneses, J. Dalmau et al.Neurology, August 01, 1995 -
Articles
Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson’s diseaseBiplob Dass, C. Warren Olanow, Jeffrey H. Kordower et al.Neurology, May 22, 2006 -
Editorials
Brain tumor therapyNew horizons, new hopeLisa M. DeAngelis et al.Neurology, May 01, 1998 -
Views & Reviews
Gene therapy of the brainThe trans-vascular approachFelix Schlachetzki, Yun Zhang, Ruben J. Boado et al.Neurology, April 26, 2004